The Zitelman Group

Venture Capital Active United States
Last updated 2026-06-18
Portfolio
1
in our dataset
Rounds participated
2
Rounds led
0
Rounds' value
$21.5M
total disclosed, rounds participated
Stages
—

Portfolio · 1

LifeBond
Biosurgery Products for Preventing Postoperative Complications
2 rounds $21.5M committed Latest: 2011-05

Investment activity

1 portfolio exit on record.

Portfolio by sector

Health Tech & Life Sciences1

Q&A

What is The Zitelman Group's most notable exit?
The Zitelman Group notably exited LifeBond in January 2020 through an acquisition by Bard Medical for $60M.
Which sectors does The Zitelman Group focus on for investments?
The Zitelman Group has shown a focus on the Health Tech & Life Sciences sector, with all its recorded portfolio companies and exits falling within this area.
Can you name a key company in The Zitelman Group's portfolio?
A key company in The Zitelman Group's portfolio was LifeBond, which developed biosurgery products.
What is the typical investment stage for The Zitelman Group?
The Zitelman Group has participated in both A Round and C Round funding stages, with one investment in each.
When was The Zitelman Group most active in new portfolio company investments?
The Zitelman Group's most recent activity in new portfolio company investments was in September 2007.
What is the most recent investment round The Zitelman Group participated in?
The Zitelman Group participated in an investment round in May 2011.